Tredje AP fonden boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 36.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,250 shares of the specialty pharmaceutical company’s stock after purchasing an additional 860 shares during the quarter. Tredje AP fonden’s holdings in Jazz Pharmaceuticals PLC were worth $505,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. LSV Asset Management purchased a new stake in Jazz Pharmaceuticals PLC in the 2nd quarter worth approximately $13,559,000. Atlantic Trust Group LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC during the 2nd quarter valued at $9,612,000. JPMorgan Chase & Co. raised its position in shares of Jazz Pharmaceuticals PLC by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares in the last quarter. Swiss National Bank raised its position in shares of Jazz Pharmaceuticals PLC by 2.8% during the 2nd quarter. Swiss National Bank now owns 218,300 shares of the specialty pharmaceutical company’s stock valued at $33,946,000 after buying an additional 6,000 shares in the last quarter. Finally, Brighton Jones LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC during the 2nd quarter valued at $213,000. Institutional investors and hedge funds own 88.24% of the company’s stock.

JAZZ has been the topic of several research reports. Deutsche Bank AG restated a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $165.11 price objective on the stock in a research report on Tuesday, June 27th. Royal Bank Of Canada set a $210.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald restated a “buy” rating and set a $197.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 27th. Finally, Janney Montgomery Scott raised their price objective on shares of Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $180.96.

TRADEMARK VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Holdings Increased by Tredje AP fonden” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/16/jazz-pharmaceuticals-plc-jazz-holdings-increased-by-tredje-ap-fonden.html.

In other news, EVP Suzanne Sawochka Hooper sold 420 shares of the stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $160.00, for a total value of $67,200.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $154.97, for a total transaction of $30,994.00. The disclosure for this sale can be found here. In the last three months, insiders sold 8,717 shares of company stock worth $1,346,617. Insiders own 4.30% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 151.48 on Friday. The firm has a 50-day moving average of $149.01 and a 200-day moving average of $150.05. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 23.33 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. During the same period in the prior year, the company posted $2.67 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.